Helsinn Healthcare Sa

Roche Palo Alto LLC

Durect Corporation

The United States Government As Represented by the Department of Veterans Affairs

Virginia Commonwealth University

Andrew R Miksztal

Roberta Cannella

Daniele Bonadeo

Thomas R Malefyt

Kathleen M Lee

Giorgio Calderari

Alberto Macciocchi

Riccardo Braglia

Enrico Braglia

Judy Joice

Susan Autio

Mark P Davis

Shunlin Ren

WeiQi Lin

Jin Koung Kim

Wilma Tamraz

Carmine Panuccio

Leyuan Xu

Yanxia Ning

Hongwei Wu

Min L Lee

Peter Langecker

Vaeling Miller

Dmitri Lissin

Adrian Neil Verity

Steven Halladay

Meej Kim

The present disclosure provides for methods of producing analgesia in a subject. In some cases, methods produce analgesia in a subject undergoing arthroscopic subacromial decompression surgery. The present disclosure also relates to improved sustained release drug delivery systems. In some cases, a composition comprises an active pharmaceutical agent; at least one of sucrose acetate isobutyrate and a polyorthoester; an organic solvent; and 2,6-dimethylaniline, wherein the 2,6-dimethylaniline is present at a level less than 500 ppm. In some cases, a composition comprises bupivacaine N-oxide at a level less than 1 wt %, based on weight of the composition. In some cases, a composition comprises metal present at a level less than 5 ppm. Dosage forms and methods are also provided.

Sustained release drug delivery systems and related methods

Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide, e.g., a cyclodextrin (CD), are provided. The compositions may be used to prevent and/or treat a variety of diseases and conditions, including organ failure (e.g. acute liver failure), high cholesterol/high lipids, and various inflammatory diseases and conditions.

Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide

The present disclosure relates to sustained release drug delivery systems. In some cases, a composition comprises an active pharmaceutical agent; at least one of sucrose acetate isobutyrate and a polyorthoester; an organic solvent; and 2,6-dimethylaniline, wherein the 2,6-dimethylaniline is present at a level less than 500 ppm. In some cases, a composition comprises N-oxide of active pharmaceutical agent at a level less than 1 wt %, based on weight of the composition. In some case, a composition comprises metal present at a level less than 5 ppm. Dosage forms and methods are also provided.

Sustained release drug delivery systems with reduced impurities and related methods

Compositions comprising 5-cholesten-3,25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide, e.g., a cyclodextrin (CD), are provided. The compositions may be used to prevent and/or treat a variety of diseases and conditions, including organ failure (e.g. acute liver failure), high cholesterol/high lipids, and various inflammatory diseases and conditions.

The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.

Liquid pharmaceutical formulations of palonosetron

Growing community of inventors

Palo Alto, CA, United States of America

Andrew R Miksztal